SBIO vs. CNCR

Last updated Jun 5, 2026

SBIO (ALPS Medical Breakthroughs ETF) and CNCR (Loncar Cancer Immunotherapy ETF) are both Health & Biotech Equities funds - SBIO tracks the S-Network Medical Breakthroughs Index while CNCR tracks the Loncar Cancer Immunotherapy Index. Both are passively managed. SBIO charges 0.50%/yr vs 0.79%/yr for CNCR.

Performance

SBIO vs. CNCR - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in ALPS Medical Breakthroughs ETF (SBIO) and Loncar Cancer Immunotherapy ETF (CNCR). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

SBIO

• 1D: 2.35%
• 1M: -5.55%
• YTD: 1.95%
• 6M: 4.13%
• 1Y: 68.86%
• 3Y*: 18.38%
• 5Y*: 3.16%
• 10Y*: 8.03%

CNCR

• 1D: 0.00%
• 1M: 0.00%
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

SBIO vs. CNCR - Yearly Performance Comparison

	2026 (YTD)
SBIO ALPS Medical Breakthroughs ETF	2.41%
CNCR Loncar Cancer Immunotherapy ETF	0.00%

SBIO vs. CNCR - Sectors Allocation Comparison

Sectors	SBIO	CNCR
Healthcare	100.0%	96.6%
Basic Materials	-	-
Communication Services	-	-
Consumer Cyclical	-	-
Consumer Defensive	-	-
Energy	-	-
Industrials	-	-
Real Estate	-	-
Technology	-	-
Utilities	-	-
Financial Services	-0.0%	3.3%

Return for Risk

SBIO vs. CNCR — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SBIO

SBIO Risk / Return Rank: 76
SBIO Sharpe Ratio Rank: 74
SBIO Sortino Ratio Rank: 72
SBIO Omega Ratio Rank: 63
SBIO Calmar Ratio Rank: 90
SBIO Martin Ratio Rank: 82

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

SBIO vs. CNCR - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for ALPS Medical Breakthroughs ETF (SBIO) and Loncar Cancer Immunotherapy ETF (CNCR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	SBIO	CNCR	Difference
Sharpe ratio: Return per unit of total volatility	2.35	—	—
Sortino ratio: Return per unit of downside risk	3.22	—	—
Omega ratio: Gain probability vs. loss probability	1.38	—	—
Calmar ratio: Return relative to maximum drawdown	5.47	—	—
Martin ratio: Return relative to average drawdown	16.23	—	—
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

Sharpe Ratios by Period

	SBIO	CNCR	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	2.35	—	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.09	—	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.24	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.22	—	—

Drawdowns

SBIO vs. CNCR - Drawdown Comparison

The maximum SBIO drawdown since its inception was -63.06%, which is greater than CNCR's maximum drawdown of 0.00%. Use the drawdown chart below to compare losses from any high point for SBIO and CNCR.

Drawdown Indicators

	SBIO	CNCR	Difference
Max Drawdown Largest peak-to-trough decline	-63.06%	0.00%	-63.06%
Max Drawdown (1Y) Largest decline over 1 year	-12.66%	—	—
Max Drawdown (3Y) Largest decline over 3 years	-42.44%	—	—
Max Drawdown (5Y) Largest decline over 5 years	-53.10%	—	—
Max Drawdown (10Y) Largest decline over 10 years	-63.06%	—	—
Current Drawdown Current decline from peak	-14.84%	0.00%	-14.84%
Average Drawdown Average peak-to-trough decline	-28.44%	0.00%	-28.44%
Ulcer Index Depth and duration of drawdowns from previous peaks	4.26%	—	—

Volatility

Volatility by Period

	SBIO	CNCR	Difference
Volatility (1M) Calculated over the trailing 1-month period	9.85%	—	—
Volatility (6M) Calculated over the trailing 6-month period	22.76%	—	—
Volatility (1Y) Calculated over the trailing 1-year period	29.40%	0.00%	+29.40%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	33.57%	0.00%	+33.57%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	33.18%	0.00%	+33.18%

SBIO vs. CNCR - Expense Ratio Comparison

SBIO has a 0.50% expense ratio, which is lower than CNCR's 0.79% expense ratio.

Dividends

SBIO vs. CNCR - Dividend Comparison

Neither SBIO nor CNCR has paid dividends to shareholders.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017
CNCR Loncar Cancer Immunotherapy ETF	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SBIO ALPS Medical Breakthroughs ETF	0.00%	0.00%	3.55%	0.22%	0.00%	0.00%	0.00%	0.04%	2.79%	1.77%

Frequently Asked Questions

Which ETF is better, SBIO or CNCR?

On fees, SBIO is cheaper at 0.50% per year. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF is cheaper, SBIO or CNCR?

SBIO is cheaper with a 0.50% expense ratio, compared with 0.79% for CNCR.

Which ETF pays a higher dividend yield, SBIO or CNCR?

SBIO and CNCR have nearly identical dividend yields, around 0.00%.

What is the main difference between SBIO and CNCR?

SBIO tracks S-Network Medical Breakthroughs Index, while CNCR tracks Loncar Cancer Immunotherapy Index. They also come from different issuers: SS&C and Exchange Traded Concepts. Their fees differ too: 0.50% for SBIO and 0.79% for CNCR.